Korro Bio Inc.

12.76
-0.14 (-1.09%)
At close: Apr 14, 2025, 3:59 PM
12.73
-0.21%
After-hours: Apr 14, 2025, 04:22 PM EDT

Company Description

Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases.

Korro Bio, Inc. is based in Cambridge, Massachusetts.

Korro Bio Inc.
Korro Bio Inc. logo
Country United States
IPO Date Oct 3, 2019
Industry Biotechnology
Sector Healthcare
Employees 104
CEO Dr. Ram Aiyar MBA, Ph.D.

Contact Details

Address:
One Kendall Square
Cambridge, Massachusetts
United States
Website https://www.korrobio.com

Stock Details

Ticker Symbol KRRO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001703647
CUSIP Number 500946108
ISIN Number US5009461089
Employer ID 47-2324450
SIC Code 2834

Key Executives

Name Position
Dr. Ram Aiyar MBA, Ph.D. Chief Executive Officer, President & Director
Todd Chappell M.B.A. Chief Operating Officer
Vineet Agarwal M.B.A. Chief Financial Officer
Andrew Fraley Ph.D. Co-Founder & Advisor
Dr. Jean-Francois Formela M.D., MBA Co-Founder & Independent Director
Dr. Joshua Rosenthal Ph.D. Co-Founder & Advisor
Dr. Loic Vincent Ph.D. Chief Scientific Officer
Jeffrey M. Cerio J.D., Pharm.D. Senior Vice President & General Counsel
Nessan Bermingham Ph.D. Co-Founder & Independent Chairman of the Board
Oliver Dolan Senior Vice President of Finance & Principal Accounting Officer

Latest SEC Filings

Date Type Title
Apr 01, 2025 4 Filing
Apr 01, 2025 4 Filing
Apr 01, 2025 3 Filing
Mar 27, 2025 8-K Current Report
Mar 18, 2025 S-8 Filing
Mar 18, 2025 10-K Annual Report
Mar 18, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 14, 2025 SCHEDULE 13G Filing
Feb 11, 2025 3 Filing